LIXTE BIOTECHNOLOGY HOLDINGS INC C/WTS 30/11/2025 (TO PUR COM) | 10-Q: FY2025 Q2 EPS: USD -0.29

LB filings
2025.08.07 12:33
portai
I'm PortAI, I can summarize articles.

EPS: As of FY2025 Q2, the actual value is USD -0.29.

EBIT: As of FY2025 Q2, the actual value is USD -774.81 K.

Segment Revenue

  • The company did not report any revenues for the three months and six months ended June 30, 2025, and 2024.

Operational Metrics

  • Net Loss: For the three months ended June 30, 2025, the net loss was $775,673, compared to $1,010,919 for the same period in 2024. For the six months ended June 30, 2025, the net loss was $1,485,228, compared to $1,982,241 for the same period in 2024.
  • Research and Development Costs: For the three months ended June 30, 2025, research and development costs were $60,648, a decrease from $210,708 in 2024. For the six months ended June 30, 2025, these costs were $152,105, down from $329,772 in 2024.
  • General and Administrative Costs: For the three months ended June 30, 2025, these costs were $714,161, compared to $798,448 in 2024. For the six months ended June 30, 2025, the costs were $1,329,644, compared to $1,646,263 in 2024.

Cash Flow

  • Operating Cash Flow: For the six months ended June 30, 2025, net cash used in operating activities was $1,055,968, compared to $1,608,266 for the same period in 2024.
  • Financing Activities: The company raised $904,228 from financing activities during the six months ended June 30, 2025, primarily from a registered direct offering.

Future Outlook and Strategy

  • Core Business Focus: The company is focused on the clinical development of LB-100, a protein phosphatase inhibitor, and has ongoing clinical trials in ovarian clear cell carcinoma, metastatic colon cancer, and advanced soft tissue sarcoma.
  • Non-Core Business: The company is considering strategic alternatives, including mergers or acquisitions, to secure additional capital and maintain its Nasdaq listing.
  • Priority: The company aims to maintain compliance with Nasdaq listing requirements and has recently completed equity financings to support its operations for at least the next 12 months.
Source: LB filings The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.